Trials / Conditions / Refractory Marginal Zone Lymphoma

Refractory Marginal Zone Lymphoma

19 registered clinical trials studyying Refractory Marginal Zone Lymphoma — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cycloph NCT06191887	Mayo Clinic	Phase 1
Active Not Recruiting	A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies NCT05828589	BeOne Medicines	Phase 1
Withdrawn	Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lym NCT04635683	Yazeed Sawalha	Phase 1
Withdrawn	Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma NCT04836832	Narendranath Epperla	Phase 1
Active Not Recruiting	ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma NCT05025800	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Withdrawn	CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL NCT04995536	City of Hope Medical Center	Phase 1
Terminated	Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refrac NCT04659044	Academic and Community Cancer Research United	Phase 2
Recruiting	Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hemat NCT04195633	Fred Hutchinson Cancer Center	Phase 2
Completed	CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymph NCT04578600	Joseph Tuscano	Phase 1
Active Not Recruiting	An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That H NCT04447716	Thomas Jefferson University	Phase 1
Active Not Recruiting	Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in P NCT04205409	University of Washington	Phase 2
Completed	Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participa NCT03583424	Ohio State University Comprehensive Cancer Center	Phase 1 / Phase 2
Active Not Recruiting	Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma NCT03479268	City of Hope Medical Center	Phase 1
Terminated	Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymph NCT03269552	University of Washington	Phase 2
Active Not Recruiting	A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Exp NCT03277729	Fred Hutchinson Cancer Center	Phase 1 / Phase 2
Completed	Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma NCT02568553	National Cancer Institute (NCI)	Phase 1
Completed	Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma NCT01995669	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Active Not Recruiting	Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma NCT01955499	National Cancer Institute (NCI)	Phase 1
Completed	Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or R NCT01381692	National Cancer Institute (NCI)	Phase 1 / Phase 2